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Abstract
Background: The last ebola virus disease (EVD) outbreak has been the most important since 1976. EVD cases
decreased drastically in Sierra Leone at the beginning of 2015. We aim to determine the clinical findings and
evolution of patients admitted to an Ebola treatment center (ETC) during the epidemic’s late phase.
Methods: We analyze retrospectively data of patients admitted to the Moyamba ETC (December 2014-March 2015).
Patients were classified in EVD or non-EVD patients according to the results of Ebola virus real-time reverse
transcription polymerase chain reaction (ZAIRE-RT-PCR).
Results: Seventy-five patients were included, 41.3 % were positive for ZAIRE-RT-PCR. More women (68 % vs 28 %,
p = 0.001) were EVD-positive. More EVD patients had previous contact with an Ebola patient (74.2 % vs 36.3 %, p < 0.
001). At admission, EVD patients were more likely to have fatigue (96.7 %, p < 0.001), diarrhea (67.7 %, p = 0.002),
and muscle pain (61.3 %, p = 0.009); but only objective fevers in 35.5 % of EVD patients. The most reliable criteria
for diagnosis were: contact with an Ebola patient plus three WHO symptoms (LR + =3.7, 95 % CI = 1.9–7.3), and
positive contact (LR + =2.3, 95 % CI = 1.15–4.20). Only 45.2 % of EVD patients developed fevers during stay, but 75 %
developed gastrointestinal symptoms. Non-EVD patients had gastrointestinal problems (33 %), respiratory
conditions (26.6 %), and others such as malaria, HIV or tuberculosis with a mortality rate of 11.4 %. vs 58 % in EVD
group (p < 0.001).
Conclusions: More non-EVD patients were admitted in the outbreak’s late phases. The low percentage of initial fever
highlights the need to emphasize the epidemiological information. EVD patients presented new symptoms getting
worse and requiring closer follow-up. Diagnoses of non-EVD patients were diverse with a remarkable mortality,
presenting a challenge for the health system.
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Background
A new Ebola treatment center (ETC) opened in the dis-
trict of Moyamba (Sierra Leone) in December 2014.
Since mid-August 2014, the district of Moyamba had
only one Holding Center to manage patients with Ebola
virus disease (EVD), and this center admitted 244 pa-
tients. The new ETC opened following collaboration of
the Department for International Development (DFID),
the Norwegian government, Solidarités International
(France), Doctors of the World (UK), and Médicos del
Mundo (Spain). The main aim of this ETC was to treat
and manage EVD cases in response to the World Health
Organization (WHO) declaration of EVD as public
health emergency of international concern on 8 August
2014, demanding the need for “a coordinated inter-
national response to stop and reverse the international
spread of Ebola because the Ebola outbreak in West
Africa constitutes an extraordinary event” [1].
The creation of ETC facilities was one of the most im-
portant factors [2] that caused a significant decrease in
the number of EVD cases during February and March
2015 throughout the country, including in the district of
Moyamba, with fewer cases of confirmed EVD among
suspected patients. For instance, during the week of 29
March 2015, there were 25 confirmed cases with EVD in
Sierra Leone (33 during the previous week) [3]. Finally,
on 7 November 2015, WHO declared Sierra Leone to be
free of Ebola.
We examined patients with suspected but uncon-
firmed EVD who were admitted to the ETC during the
final stages of this epidemic. To increase public health
knowledge, this paper also covers information about the
EVD negative patients admitted in Moyamba ETC.
The specific purposes of the present study were to:
– Compare the clinical characteristics of confirmed
cases (EVD patients) and non-confirmed cases
(non-EVD patients) treated at the ETC in Moyamba.
– Assess the diagnostic validity of initial symptoms
used in WHO case definition to diagnose EVD in a
low-incidence situation.
– Describe the symptoms of the patients during the
stay in the ETC.
– Know information about the presumptive diagnosis
of non-EVD patients.
Methods
This is a retrospective observational study. The study
population consists of all patients admitted for treatment
at the Moyamba ETC from December 2014 to March
2015. All patients were referred to the ETC after an epi-
demiological investigation carried out by government
epidemiological research teams who were specifically
trained to apply WHO standard criteria for the diagnosis
of EVD (Table 1) [4, 5]. To identify potential probable
cases of EVD that would need special care and isolation
during their admission, all patients were re-examined in
the triage zone of the ETC. Patients were admitted to a
pavilion for those with suspected EVD or a pavilion for
those with probable EVD depending on clinical findings,
history of contact with a confirmed case of EVD, or at-
tendance at a funeral of a case with confirmed EVD. On
admission, standardized treatment was started according
to protocols based on the guidelines WHO and
Médecins Sans Frontieres (MSF), later modified from the
“Hastings protocol” [6]. Real-time reverse transcription
polymerase chain reaction (ZAIRE-RT-PCR) for EVD
was performed for all admitted patients, and those with
positive results were immediately transferred to a pavil-
ion designated for EVD confirmed patients.
The patient clinical variables that we examined were
selected based on previous publications [7, 8]. History of
symptoms were demanded at admission, and were regis-
tered (presence of fever or feverish at home, time since
the onset of symptoms, government epidemiological
teams information). Initial symptoms were screened
once more at admission, taking the temperature in this
moment. Information about treatments or chronic dis-
eases was asked, but information about antipyretic medi-
cation was not always recorded. Clinical information
was recorded in MS Word® for the clinical records and
MS Excel® for the standardized information. All data
Table 1 WHO case definitions for Ebola virus disease during an
epidemic
A suspect case is any person:
• Having had contact with a clinical case AND
• Presenting with acute fever (>38 °C)
OR
• Having had contact with a clinical case (suspect, probable or
confirmed) AND
• Presenting with 3 or more of the symptoms below:
OR
• Presenting with acute fever AND
• Presenting with 3 or more of the concerning symptoms below:
○ Headache
○ Abdominal pain
○ Generalized or articular pain
○ Difficulty in swallowing
○ Intense fatigue
○ Difficulty in breathing
○ Nausea or vomiting
○ Hiccups




• Any person with unexplained bleeding or miscarriage
OR
• Any unexplained death.
Adapted from: Gove S, Wurie A, IMAI-IMCI Alliance. Clinical management of
patients in the ebola treatment centres and other care centres in Sierra Leone.
Adaptation of the WHO generic. Ed MOHS. December 2014
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were collected as part of the daily routine patient care
and recorded on a paper based clinical charts and kept
securely on standardized forms. Data extracted for re-
search purposes were anonymised and stored in a
password-protected database. The Sierra Leone Ethics
and Scientific Review Committee and the Western Nor-
wegian Regional Committee for Medical and Health Re-
search Ethics approved the study.
Diagnostic services were provided by the US Centers
for Disease Control (CDC) laboratory using the Ebola
virus (Zaire) nucleoprotein and the real-time reverse
transcription polymerase chain reaction (ZAIRE RT-
PCR) in Bo (Sierra Leone) before 12 January 2015, and
on-site by the US DoD MEDaC Laboratory thereafter.
Descriptive analysis was performed by calculating fre-
quencies with proportions for categorical variables and
means with standard deviations or medians and quartiles
(depending on the distribution of variable) for continu-
ous variables. To test the association between each vari-
able and outcome (diagnosis of EVD), chi square/
Fisher’s exact test or Student’s t-test/Mann–Whitney U
test was used. A p-value less than 0.05 was considered
statistically significant. Sensitivity, specificity, positive
and negative likelihood ratios (LR+ and LR-), and posi-
tive and negative predictive values (PPV and NPV) were
calculated with 95 % confident intervals (CIs) for each
clinical variable and WHO criterion. Microsoft Excel®
and IBM® SPSS® Statistics ver. 20 were used for data
analysis.
Given the absence of complementary explorations in
an ETC, the presumptive diagnosis in non-EVD patients
were made by consensus of the clinician team based on
symptoms and previous history. Some of these diagnoses
were confirmed by district hospital during the days after
discharge (blood tests, response to treatment).
Results
Basic characteristics of EVD and non-EVD patients
From December 2014 to March 2015, 92 patients were
admitted to the ETC in Moyamba (Sierra Leone). A total
of 81.5 % (75/92) were admitted because they had symp-
toms of EVD and 18.5 % (17/92) because they were rela-
tives or caregivers of patients admitted with symptoms
or had previous contact with an EVD patient. Individuals
in this last group were RT-PCR negative for EVD in two
test and were excluded from our analysis because
they did not complain of any symptoms during their
stays or during the 21 days period of isolation after their
admission (Fig. 1). During this stage of the epidemic,
there were more non-confirmed/suspected patients
(non-EVD, n = 44, 58.7 %) than confirmed cases (EVD,
n = 31, 41.3 %) (Fig. 1).
The overall mean patient age was 34 years (range:
0 months–80 years), and 66.7 % (50/75) were men.
Table 2 shows characteristics of the non-EVD and EVD
groups. More women were confirmed EVD patients
68 % (17/25) vs. 28 % (14/50) in men with significant dif-
ferences (p = 0.001). Epidemiological information about
contact history was unknown in 17 % (13/75) of the in-
cluded patients. The EVD group had a higher percentage
of individuals with a history of contact with confirmed
patients (74.2 % vs. 36.3 %, p < 0.001), of individuals who
met any WHO criterion for suspected EVD at admission
(87 % vs. 59 %, p = 0.01), and of individuals who had one
of three WHO criteria for suspected EVD at admission
(contact and fever, contact and 3 symptoms, and unex-
plained bleeding, p < 0.05 for each). The EVD group also
had a longer median stay at the ETC (7 days [IQR: 3–12
days] vs. 4 days [IQR: 2–6 days], p = 0.004), and a greater
mortality rate (58 % vs. 11.4 %, p < 0.001).
Clinical features of EVD and non-EVD patients
The main initial symptoms of all suspected patients in
Moyamba ETC were: fatigue 75 % (55/75), fever history
or observed on admission 67 % (50/75), anorexia 48 %
(36/50), diarrhea, abdominal pain and headache with
45 % (34/75) each, joint pain 44 % (33/75), muscle pain
43 % (32/75) and vomiting 41 % (31/75).
Table 3 shows the presence of initial symptoms and
the development of symptoms during the stay at the
ETC for patients in the EVD and non-EVD groups, with
significant factors. This analysis indicates that patients in
the EVD group were significantly more likely to have fa-
tigue (96.7 % vs. 56.8 %, OR = 22.8, p < 0.001), diarrhea
(67.7 % vs. 29.5 %, OR = 5, p = 0.002), muscle pain
Fig. 1 Disposition of patients admitted to the Ebola Treatment
Center in Moyamba (Sierra Leone) from December 2014 to March
2015: Total admissions 92, excluded (no symptoms) 17 (18.5 %),
included (symptoms) 75 (81.5 %), Non Ebola virus cases 44 (58.6 %)
and Ebola virus cases 31 (41.4 %)
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(61.3 % vs. 29.5 %, OR = 3.8, p = 0.009), vomiting (58 %
vs. 29.5 %, OR = 3.3, p = 0.018), dysphagia (eight patients
vs. none, OR = 0.3, p < 0,001) and bleeding (11 patients
vs. none, OR = 0.3, p < 0.001). Fever was measured at ad-
mission and every day until the discharge, only 35.5 % of
EVD patients and 34 % of non-EVD patients was ob-
served having fever at admission. But if we join patients
with objective fever and those with history of fever at
home, the percentages increase to 61.3 % of EVD pa-
tients and 70.4 % of non-EVD patients.
Diagnostic value of initial symptoms
Table 4 shows the diagnostic value of all initial symp-
toms, including WHO criteria, with significant factors.
Upon admission, the highest sensitivities for confirmed
EVD were for history of contact with an EVD confirmed
person (100 %, 95 % CI: 100–100 %), and fatigue
(96.8 %, 95 % CI: 90.6–100 %). The sensitivity was some-
what greater when assessing symptoms together, with
96.8 % (95 % CI: 90.6–100 %) for fatigue and anorexia
and 83.9 % (95 % CI: 70.9–96.8 %) for digestive symp-
toms. The PPVs for initial symptoms were all relatively
low except for presence of bleeding and dysphagia
(100 %, 95 % CI: 100–100 %)/. Although the presence of
any WHO criterion had a relatively high sensitivity
(87.1 %, 95 % CI: 75.3–98.9 %), it had a low specificity
(40.9 %, 95 % CI 26.4–55.4 %) and a low PPV (50.9 %,
95 % CI: 37.5–64.4 %). Based on LRs, the best diagnostic
criteria were: (i) confirmed contact with an Ebola patient
plus 3 WHO symptoms (LR+ = 3.7, 95 % CI = 1.9–7.3;
LR- = 0.4, 95 % CI = 0.2–0.7), (ii) have had contact
(LR+ = 2.3, 95 % CI = 1.15–4.20; LR- = 0.65, 95 % CI =
0.44–0.95), and (iii) diarrhea (LR+ = 2.3, 95 % CI = 1.4–
3.8; LR- = 0.5, 95 % CI = 0.3–0.8).
Evolution of patients
During the stay in the ETC, patients in the EVD group
were significantly more likely than the non-EVD group
to have symptoms of dysphagia (51.6 % vs. 13.6 %, OR =
6.7, p = 0.001), vomiting (74.2 % vs. 43.7 %, OR = 5.2, p =
0.001), muscle pain (71 % vs. 29.5 %, OR = 6 p < 0.001),
or bleeding (51.6 % vs zero, p < 0.001), and additional
symptoms of chest pain (58 % vs. 27.2 %, OR = 3.7, p
= 0.009), red eyes (48.3 % vs. 18 %, OR = 4.2, p =
0.01), coma/unconsciousness (29 % vs. 2.3 %, OR = 17.6,
p = 0.001), and confusion/disorientation (45 % vs. 15.9 %,
OR = 4.3, p = 0.01). EVD patients developed fever only in
45.2 % (14/31) without differences with non-EVD group.
In the subgroup of patients without initial fever (objective
or referred) EVD patients developed fever in 50 % (6/12)
without differences with non-EVD group, 46.2 % (6/13).
A presumptive diagnosis was possible in 68 % (30/44)
of the non-EVD patients. Gastrointestinal and hepatic
conditions were the most frequent presumptive diagnos-
tic conditions (33.3 %, 10/44), followed by respiratory
problems (26.6 %, 8/44), malaria (13.3 %, 4/44), previ-
ously known HIV (8.8 %, 3/44), and clinical Pott’s dis-
ease, diabetes mellitus, urethral syndrome, abdominal
tumor, or cardiac conditions (2.3 % and 1 case each).
More than two-thirds of all admitted patients (69.7 %,
53/76), recovered and were discharged. Non-EVD pa-
tients were more likely to recover and be discharged
(88.6 % vs. 42 %, p < 0.001). Most non-EVD patients
(68 %, 30/44) were sent home or to a convalescent or
quarantine center, 9 were transferred to the Moyamba
District Hospital, and 5 died at the ETC. All patients
treated at the Moyamba District Hospital were dis-
charged to their homes and were in good health several
days after transfer.
Table 2 Sociodemographic characteristics of patients with non-
confirmed Ebola virus disease (non-EVD) and confirmed EVD
who were treated in the Ebola Treatment Center in Moyamba





Non-EVD Number (%) EVD Number (%) P value
Included patients 44 (58.7) 31 (41.3)
Sex
Male 36 (82) 14 (45.1)
Female 8 (18) 17 (54.8) 0.001
Age (years)
Median (1–3 Q) 40 (23–48) 30 (17–40) 0.095
Range (months-years) 0–80 0–85
History of contact with an Ebola patient
Yes 16 (36.3) 23 (74.2) <0.001
No 23 (52.3) 0 (−)
Unknown 5 (11.3) 8(25.8)
Suspect criteria
Contact + Fever 10 (22.7) 15 (48.4) 0.026
Contact + 3 symptoms 8 (18) 21 (67.7) <0.001
Fever + 3 symptoms 22 (50) 18 (58) 0.639
Bleeding 0 (−) 11 (35.5) <0.001
Any WHO criterion 26 (59) 27 (87) 0.01
Onset symptoms (days)
Median (1–3 Q) 2(1–6) 3 (1–5) 0.564
Stay length (days)
Median (1–3 Q) 4 (2–6) 7(3–12) 0.004
State at discharge
Alive 39 (88.6) 13 (42) <0.001
Dead 5 (11.4) 18 (58)
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Discussion
International help for the 2014 Ebola epidemic arrived late
in Moyamba, as in other places in Sierra Leone, and open-
ing a new ETC in the field was difficult. Between August
and December 2014, 244 patients were isolated at the small
Holding Center in Moyamba, and 149 of them had con-
firmed EVD. Between December 2014 and March 2015, 75
patients were admitted for treatment to the ETC in
Moyamba, and 42 % of them had confirmed EVD. At this
ETC, as in others constructed in Sierra Leone, the number
of patients admitted never reached the center’s capacity
(100 beds). The Sierra Leonean Minister of Health declared
the district free of Ebola in April 2015, and we have detailed
clinical information of all patients treated at this ETC.
Unlike other ETCs, the ETC in Moyamba treated all EVD-
positive patients and suspected patients or contacts due to
directives from the District Ebola Response Center (DERC)
[9]. The striking decrease in incidence of EVD beginning in
February 2014 led to changes in the ETCs, because many
suspected cases required isolation until their statuses were
confirmed. At that time, we decided to assess the diagnostic
validity of EVD symptoms in a low incidence situation and
to follow the presumptive diagnoses, evolution, and dis-
charge of non-EVD patients.
Our study shows that in Moyamba ETC females
were more likely to have EVD than males (17/25,
Table 3 Initial symptoms and evolution of symptoms in patients with non-confirmed Ebola virus disease (non- EVD) and confirmed
EVD who were treated at the Ebola Treatment Center in Moyamba (Sierra Leone) from December 2014 to March 2015
Initial symptoms Evolution symptoms
Symptoms Non-EVD N = 44
Number (%)
EVD N = 31
Number (%)
Unadjusted odds
ratio (95 % CI)a
P value Non-EVD N = 44
Number (%)
EVD N = 31
Number (%)
Unadjusted odds
ratio (95 % CI)
P value
Feverb 31 (70.4) 19 (61.3) 0.6 (0.2–1.7) 0.461
Objective
Fever (>38 °C)
15(34) 11 (35.5) 1 (0.4–2.6) 0.585 11 (25) 14 (45.2) 2.3 (0.9–6.6) 0.085
Vomiting 13 (29.5) 18 (58) 3.3 (1.3–8.7) 0.018 14 (43.7) 23 (74.2) 5.2 (2.2–17.2) <0.001
Diarrhea 13 (29.5) 21 (67.7) 5 (1.8–13.5) 0.002 18 (40.9) 24 (77.4) 5 (1.8–14) 0.002
Fatigue 25 (56.8) 30 (96.7) 22.8 (2.8–182.4) <0.001 29 (65.9) 31 (100) 15.5 (2–125.1) 0.001
Anorexia 17 (38.6) 19 (61.3) 2.5 (0.9–6.4) 0.064 19 (43.1) 27 (87) 8.9 (2.6–29.7) <0.001
Abdominal
pain
20 (45.4) 14 (45) 1 (0.4–2.5) 1 25 (56.8) 22 (71) 1.9 (0.7–5) 0.236
Chest pain 9 (20.4) 7 (22.5) 1 (0.4–3.5) 1 12 (27.2) 18 (58) 3.7(1.4–9.8) 0.009
Muscle pain 13 (29.5) 19 (61.3) 3.8 (1.4–9.9) 0.009 13 (29.5) 22 (71) 6 (2.7–16) <0.001
Joint pain 17 (38.6) 16 (51.6) 1.7 (0.7–4.3) 0.346 19 (43.1) 19 (61.3) 2 (0.8–5.3) 0.161
Headache 17 (38.6) 17 (54.8) 1.9 (0.8–4.9) 0.239 24 (54.5) 18 (58) 1.1 (0.5–3) 0.816
Back pain 3 (6.8) 2 (6.4) 0.9 (0.1–5.8) 1 7(15.9) 7 (212.6) 1.5 (0.5–5) 0.552
Pain behind
eyes
0 (0) 0 (0) * (*) * (*) 0 (0) 0 (0) * (*) * (*)
Cough 0 (0) 0 (0) * (*) * (*) 17 (38.6) 12 (38.7) 1 (0.4–2.5) 1
Breathing
problems
0 (0) 0 (0) * (*) * (*) 7(15.9) 7 (21.9) 1.5 (0.5–4.9) 0.552
Dysphagia 0 (0) 8 (25.8) *(*) <0.001 6 (13.6) 16 (51.6) 6.7 (2.2–20.5) 0.001
Sore throat 0 (0) 0 (0) * (*) * (*) 2 (4.5) 1 (3.2) 0.7 (0.06–8) 1
Jaundice 3 (6.8) 0 (0) * (*) * (*) 4 (9) 0 (0) * (*) * (*)
Red eyes 8 (18) 12 (38.7) 2.8 (1–8.1) 0.065 8 (18) 15 (48.3) 4.2 (1.5–12) 0.01
Skin rash 1 (2.3) 1 (3.2) 1.4 (0.08–24) 1 1 (2.3) 1 (3.2) 1.4 (0.1–23) 1
Hiccups 6 (13.6) 2 (6.4) 0.4 (0.08–2.3) 0.457 6 (13.6) 2 (6.4) 0.4 (0.08–2.3) 0.457
Coma /
unconscious
0 (0) 0 (0) * (*) * (*) 1 (2.3) 9 (29) 17.6 (2–147.8) 0.001
Confused /
disoriented
4 (9) 1 (3.2) 0.3 (0.03–3) 0.397 7(15.9) 14 (45) 4.3 (1.5–12.7) 0.009
Bleeding 0 (0) 11 (35.5) * (*) <0.001 0 (0) 16 (51.6) * (*) <0.001
a 95 % CI: 95 % confidence interval
b If the patient reported having a fever or was >38 °C upon admission
* = OR and/or 95 % CI not applicable
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68 % vs. 14/50, 28 %, p = 0.001). This study also high-
lights the importance of determining the detailed epi-
demiological histories of individuals admitted to an
ETC and whether they were exposed to patients with
EVD between 2 and 21 days before presentation. In
patients where the epidemiological information was
known, our data showed that 74.2 % of EVD patients
(but only 36 % of non-EVD patients) had previous
contact with an affected patient. Other studies have
also emphasized the importance of previous contact
with EVD patients [10]. Lado et al. reported much
lower percentages of EVD-positive subjects following
contact with infected individuals, (but with less de-
tailed observations and follow-up) [11].
The presence of fatigue, digestive symptoms (diarrhea,
vomiting, dysphagia), muscle pain, and bleeding were
the most common initial symptoms of EVD patients in
our center, as in previous studies [5, 10, 12, 13]. How-
ever, in our study a relatively low percentage of EVD pa-
tients had objective fever at admission and during their
stays at the ETC, without statistical differences between
the two groups of patients. This seems surprising as
fever was one of the major criteria for diagnosis of EVD,
and is even considered a very important part of WHO
criteria for suspicion of EVD. Schieffelin [4] and other
researchers observed even lower percentages of objective
fever in Ebola patients. These low rates of fever may
partly be explained by the widespread administration of
paracetamol to admitted patients.
The algorithms developed to identify suspected cases
of EVD were based on definitions as established by the
WHO and a consensus of experts [14]. However, the re-
liability of this approach for diagnosis of EVD has not
been established [14]. In our study, the WHO criteria
Table 4 Diagnostic value of initial symptoms in patients admitted to the Moyamba Ebola Treatment Center
Sensitivity (95 % CI) Specificity (95 % CI) Likelihood ratio
positive (95 % CI)
Likelihood ratio
negative (95 % CI)
PPV (95 % CI) NPV (95 % CI)
Contact 100 (*) 59 (43.5–74.4) 2.4 (1.7–3.6) * 59 (43.5–74.4) 100 (*)
Fever (≥38 °C or referred) 61.3 (44.1–78.4) 29.5 (16.1–43) 0.9 (0.6–1.2) 1.3 (0.7–2.5) 38 (24.5–51.5) 52 (32.4–71.6)
Vomiting 58.1 (40.7–75.4) 70.5 (57–83.9) 2 (1.1–3.4) 0.6 (0.4–1.0) 58.1 (40.7–75.4) 70.5 (57–83.9)
Diarrhea 67.7 (51.3–84.2) 70.5 (57–83.9) 2.3 (1.4–3.8) 0.5 (0.3–0.8) 61.8 (45.4–78.1) 75.6 (62.5–88.8)
Fatigue 96.8 (90.6–100) 43.2 (28.5–57.8) 1.7 (1.3–2.2) 0.1 (0–0.5) 54.5 (41.4–67.7) 95 (85.4–100)
Anorexia 61.3 (44.1–78.4) 61.4 (47–75.8) 1.6 (1–2.5) 0.6 (0.4–1) 52.8 (36.5–69.1) 69.2 (54.7–83.7)
Abdominal pain 45.2 (27.6–62.7) 54.5 (39.8–69.3) 1 (0.6–1.6) 1 (0.7–1.6) 41.2 (24.6–57.7) 58.5 (43.5–73.6)
Chest pain 22.6 (7.9–37.3) 79.5 (67.6–91.5) 1.1 (0.5–2.6) 1.0 (0.8–1.2) 43.8 (19.4–68.1) 59.3 (46.8–61.9)
Muscle pain 61.3 (44.1–78.4) 70.5 (57–83.9) 2.1 (1.2–3.5) 0.5 (0.3–0.9) 59.4 (42.4–76.4) 72.1 (58.7–85.5)
Joint pain 51.6 (34–69.2) 61.4 (47–75.8) 1.3 (0.8–2.2) 0.8 (0.5–1.2) 48.5 (31.4–65.5) 64.3 (49.8–78.8)
Headache 54.8 (37.3–72.4) 61.4 (47–75.8) 1.4 (0.9–2.3) 0.7 (0.5–1.2) 50 (33.2–66.8) 65.9 (51.3–80.4)
Back pain 6.5 (0–15.1) 93.2 (85.7–100) 0.9 (0.2–5.3) 1.0 (0.9–1.1) 40.0 (−2.9–82.9) 58.6 (47.0–70.1)
Dysphagia 25.8 (10.4–41.2) 100 (*) * 0.7 (0.6–0.9) 100 (*) 65.7 (54.3–77)
Red eyes 38.7 (21.6–55.9) 81.8 (70.4–93.2) 2.1 (1–4.6) 0.7 (0.5–1) 60 (38.5–81.5) 65.5 (47.6–70.2)
Skin rash 3.2 (0–9.4) 97.7 (93.3–100) 1.4 (0.1–21.8) 1.0 (0.9–1.1) 50.0 (0–100) 58.9 (47.6–70.2)
Hiccups 6.5 (0–15.1) 86.4 (76.2–96.5) 0.5 (0.1–2.2) 1.1 (1.0–1.3) 25 (0–55) 56.7 (44.9–68.6)
Confused / disoriented 3.2 (0–9.4) 90.9 (82.4–99.4) 0.3 (0–3) 1.1 (1.0–1.2) 20.0 (0–55.1) 57.1 (45.5–68.7)
Bleeding 35.5 (18.6–52.3) 100 (*) * 0.6 (0.5–0.8) 100.0 (*) 68.8 (57.4–80.1)
Fatigue/anorexia 96.8 (90.6–100) 38.6 (24.2–53.0) 1.10 (0.79–1.55) 0.83 (0.44–1.57) 43.8 (29.7–57.8) 63.0 (44.7–81.2)
Digestive symptoms 83.9 (70.9–96.8) 45.5 (30.7–60.2) 1.54 (1.13–2.10) 0.35 (0.15–0.84) 52.0 (38.2–65.8) 80.0 (64.3–95.7)
Musculoskeletal pain 67.7 (51.3–84.2) 38.6 (24.2–53.0) 1.10 (0.79–1.55) 0.83 (0.44–1.57) 43.8 (29.7–57.8) 63.0 (44.7–81.2)
Headache / Pain behind eyes 54.8 (37.3–72.4) 61.4 (47.0–75.8) 1.42 (0.87–2.32) 0.74 (0.47–1.16) 50.0 (33.2–66.8) 65.9 (51.3–80.4)
Neurological symptoms 3.2 (0–9.4) 90.9 (82.4–99.4) 0.35 (0.04–3.02) 1.06 (0.95–1.19) 20.0 (0–55.1) 57.1 (45.5–68.7)
Contact + Fever 48.4 (30.8–66) 77.3 (64.9–89.7) 2.1 (1.1–4.1) 0.7 (0.5–1) 60 (40.8–79.2) 68.0 (55.1–80.9)
Contact + 3 symptoms 67.7 (51.3–84.2) 81.8 (70.4–93.2) 3.7 (1.9–7.3) 0.4 (0.2–0.7) 72.4 (56.1–88.7) 78.3 (66.3–90.2)
Fever + 3 symptoms 58.1 (40.7–75.4) 50 (35.2–64.8) 1.2 (0.8–1.8) 0.8 (0.5–1.4) 45 (29.6–60.4) 62.9 (46.8–78.9)
Any WHO criterion 87.1 (75.3–98.9) 40.9 (26.4–55.4) 1.5 (1.1–1.9) 0.3 (0.1–0.8) 50.9 (37.5–64.4) 81.8 (65.7–97.9)
NPV negative predictive value, PPV positive predictive value
* = 95%CI not applicable
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had acceptable sensitivity (87.1 %), but low specificity
(40.9 %) and low PPV (50.9 %), as in other studies [10].
The most reliable criteria were contact with an infected
person plus three symptoms (LR+ of 3.7 and NPV of
78.3 %), diarrhea (LR+ of 2.3 and NPV of 75.6 %), and
contact with an infected person and fever (LR+ of 2.1
and NPV of 68 %). As in other studies [9, 10], unex-
plained bleeding at presentation had high specificity
(100 %), but low sensitivity (35.5 %). Other authors have
attempted to improve the suspected case definition
using diagnostic scores, but achieved no improvement in
specificity [10]. Taken together, these results emphasize
the limitations of these diagnostic criteria and the need
for fast and reliable laboratory tests upon admission to
an ETC [15–17].
One of the important aspects of our study is that we
followed the evolution of EVD and non-EVD patients
following admission to the ETC. As expected, some
symptoms became more common while patients were in
the ETC. About 75 % of the EVD patients had increased
gastrointestinal symptoms (vomiting, diarrhea, dysphagia
or anorexia) while in the ETC, considered by Hunt et al.
[9] to be a sign of stage-2 disease. Pain in different loca-
tions (muscular, chest pain) also became more common
among admitted patients. Moreover, 50 % of admitted
patients had symptoms that implied more severe stage-3
disease [9], namely bleeding/hemorrhage and neuro-
logical symptoms (confusion or coma). Previous studies
reported that less than 15 % of patients with EVD pre-
sented with bleeding [4, 10, 11, 16], but 35.5 % of EVD
patients in ETC Moyamba had bleeding on admission
and 51.6 % developed bleeding during their stays at the
ETC. This was related to a poor prognosis [13].
Patients admitted to the ETC who did not have EVD
had diverse clinical conditions, with a predominance of
gastrointestinal problems, respiratory problems, and
malaria. Some of the non-EVD patients had clinical
Pott’s disease, known HIV infection, or possibly cardiac
conditions (clinically compatible with myocardial infarc-
tion). Up to 11.4 % of these patients died at the ETC (a
remarkable part of overall mortality), one patient with
known HIV infection, another patient with respiratory
problem, a man with cardiac condition and two patients
for unknown reasons. These findings point to the com-
plexities involved in handling non-EVD patients at an
ETC during an epidemic.
In our series, the death rate of patients with EVD was
58 %. In other studies of EVD the death rates were be-
tween 37 and 74 % [4, 9, 11, 18], although some studies
reported that more than 50 % of patients were lost to
follow-up [14]. Recent articles highlighted the uncer-
tainty as to whether the clinical management of patients
in this epidemic could have been improved, and what
should be done in future epidemics [19, 20]. The training
of healthcare staff in ETCs and the treatment protocols
used in ETC Moyamba and in most ETCs were based on
guidelines developed by the WHO and Médecins Sans
Frontieres. These guidelines emphasize use of quarantine
and epidemic control, but patient care is based on patient
history and examinations. The examination, however may
be difficult to perform and will be incomplete. Other stud-
ies [9, 19–23] have shown that more than 30 % of the
EVD patients had acute renal insufficiency and abnormal
potassium concentrations, and the association of acute
renal insufficiency, hepatitis, and rhabdomyolysis with
death from EVD demonstrates the need to monitor elec-
trolytes and other laboratory parameters to improve the
management and care of such patients.
Limitations of the study
The main limitation of this study is its retrospective design.
The work was done in a complicated clinical scene, where
it could be difficult to obtain certain information. Data ana-
lysis was done on charts that were filled by different health-
care workers, and some information could be lacking. We
know that the small number of patients and the participa-
tion of only one ETC in this study, limit the capability to
generalize our conclusions to other ETCs, but we think our
data give some useful information to the actual knowledge
of the disease and we show the difficulties in performing
complete clinical diagnoses at the ETC and the district hos-
pital to which non-EVD patients were transferred.
Conclusion
Our study shows a low specificity and PPV for WHO
criteria in the late phases of the epidemics with more
non-EVD patients admitted in an ETC. The low percent-
age of patients with fever at admission and during their
stay at the ETC, our study highlights the importance
of collecting detailed and complete epidemiological his-
tories of patients with suspected EVD.
Our study detects a development of new symptoms
and increase of initial symptoms related with a poor
prognosis of most EVD patients after admission to the
ETC. Therefore, such patients must be followed as
closely as possible, although this can be difficult in the
presence of an Ebola epidemic. Our presumptive diagno-
ses of non-EVD patients were diverse indicating that the
ETCs and district hospitals must be better prepared and
interrelated for a proper care of all suspected patients
during the final phases of an Ebola epidemic.
We believe it may be advisable to modify some of the
protocols used to care for patients admitted to an ETC.
In particular, monitoring of electrolytes and other la-
boratory parameters may allow better management of
patients with EVD and provide a safer and more appro-
priate method of care.
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To improve the relationship between ETCs and health
facilities (district hospitals, health centers), in the late
phases of an outbreak, is a big challenge to assure a cor-
rect care to the Non-EVD patients.
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